DAVITA INC. DVA

Healthcare SIC 8090 - Services-Misc Health & Allied Services, NEC NAICS Health Care and Social Assistance › Ambulatory Health Care Services › Outpatient Care Centers › Other Outpatient Care Centers › Kidney Dialysis Centers derived NYSE

Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at http://www.davita.com, as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC). The SEC also maintains a website at http://www.sec.gov where these reports and other information about us can be obtained. The contents of our website are not incorporated by reference into this report.

Last close 183.64 2026-10-23
Market cap $11.72B 2026-06-30 share count
52-week range 101.00 - 247.49

Valuation FY2025 figures against the last close

P/S0.9x
P/E18.7x
P/FCF8.9x
EV/EBITDA4.3x
Dividend yield0.0%
Diluted EPS9.84

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $13.64B$12.82B$12.14B$11.61B$11.62B$11.55B$11.39B$10.71B$10.09B$9.73B
SG&A $1.67B$1.54B$1.47B$1.36B$1.20B$1.25B$1.10B$1.14B$1.06B$1.07B
Total operating expenses $11.60B$10.73B$10.54B$10.27B$9.82B$9.86B$9.75B$9.88B$9.06B$8.68B
Operating income $2.04B$2.09B$1.60B$1.34B$1.80B$1.69B$1.64B$1.53B$1.81B$2.03B
Pre-tax income $1.35B$1.53B$1.18B$966.3M$1.52B$1.32B$1.20B$1.05B$1.40B$1.62B
Income tax $293.1M$279.7M$220.1M$198.1M$306.7M$313.9M$279.6M$258.4M$323.9M$431.8M
Net income $1.08B$1.25B$957.0M$781.6M$1.21B$773.6M$811.0M$159.4M$663.6M$879.9M
EPS, basic 10.0611.027.626.039.306.465.290.933.524.36
EPS, diluted 9.8410.737.425.858.906.315.270.923.474.29
Shares, diluted (wtd. avg.) 75.9M87.3M93.2M95.8M109.9M122.6M153.8M172.4M191.3M204.9M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $676.4M$794.9M$464.6M$339.0M$555.0M$501.8M$1.21B$415.4M$518.9M$683.5M
Short-term investments $24.3M$51.1M$11.6M$77.7M$22.3M$20.1M$11.6M$2.9M$32.8M$307.0M
Receivables $2.41B$2.15B$1.99B$2.13B$1.96B$1.82B$1.80B$1.86B$1.71B$1.50B
Inventory $160.6M$134.6M$143.1M$109.1M$107.4M$111.6M$97.9M$107.4M$181.8M$160.4M
Total current assets $4.06B$3.75B$3.14B$3.16B$3.17B$3.15B$3.69B$8.42B$8.77B$3.99B
Property, plant and equipment $2.81B$2.94B$3.07B$3.26B$3.48B$3.52B$3.47B$3.39B$3.15B$2.86B
Goodwill $7.55B$7.38B$7.11B$7.08B$7.05B$6.92B$6.79B$6.84B$6.61B$6.02B
Other intangibles $222.1M$197.4M$203.2M$182.7M$177.7M$166.6M$135.7M$118.8M$113.8M$73.5M
Total assets $17.48B$17.29B$16.89B$16.93B$17.12B$16.99B$17.31B$19.11B$18.97B$18.76B
Accounts payable $696.1M$547.2M$514.5M$479.8M$402.0M$434.3M$403.8M$463.3M$509.1M$456.6M
Total current liabilities $3.14B$2.97B$2.64B$2.62B$2.40B$2.48B$2.37B$4.89B$3.07B$2.71B
Total liabilities $16.32B$15.19B$14.15B$14.70B$14.75B$14.09B$13.81B$14.08B$13.08B$12.93B
Retained earnings -$328.4M$1.53B$598.3M$174.5M$354.3M$852.5M$1.43B$2.74B$3.63B$3.71B
Total equity -$651.1M$121.1M$1.06B$712.3M$755.5M$1.38B$2.13B$3.70B$4.69B$4.65B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $1.89B$2.02B$2.06B$1.56B$1.93B$1.98B$2.07B$1.77B$1.91B$1.97B
Depreciation and amortisation $708.3M$716.4M$736.5M$721.1M$667.8M$616.6M$600.9M$574.8M$544.1M$494.9M
Stock-based compensation $140.0M$102.8M$112.4M$95.4M$102.2M$91.5M$67.8M$73.1M$35.1M$38.3M
Capital expenditure $575.9M$555.4M$568.0M$603.4M$641.5M$674.5M$766.5M$987.1M$905.2M$829.1M
Investing cash flow -$654.9M-$771.4M-$771.8M-$630.3M-$784.7M-$825.4M$3.00B-$1.01B-$1.36B-$1.20B
Financing cash flow -$1.37B-$816.9M-$1.17B-$1.12B-$1.08B-$1.85B-$4.70B-$625.4M-$766.3M-$1.35B
Dividends paid $0$0$0$0$0$0$0$0——
Buybacks $1.31B$1.39B$272.2M$802.2M$1.54B$1.46B$2.38B$1.16B$802.9M$1.10B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000927066-26-000053.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 5B 10B 15B Revenue, FY2016: 9.7B Net income, FY2016: 879.9M Revenue, FY2017: 10.1B Net income, FY2017: 663.6M Revenue, FY2018: 10.7B Net income, FY2018: 159.4M Revenue, FY2019: 11.4B Net income, FY2019: 811M Revenue, FY2020: 11.6B Net income, FY2020: 773.6M Revenue, FY2021: 11.6B Net income, FY2021: 1.2B Revenue, FY2022: 11.6B Net income, FY2022: 781.6M Revenue, FY2023: 12.1B Net income, FY2023: 957M Revenue, FY2024: 12.8B Net income, FY2024: 1.3B Revenue, FY2025: 13.6B Net income, FY2025: 1.1B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $9.73B $10.09B $10.71B $11.39B $11.55B $11.62B $11.61B $12.14B $12.82B $13.64B
Gross profit — — — — — — — — — —
Net income $879.9M $663.6M $159.4M $811.0M $773.6M $1.21B $781.6M $957.0M $1.25B $1.08B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Material agreement signed Item 1.01
  • New debt or obligation Item 2.03
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8090

TickerCompanyMarket capP/ERevenue growth
SHC Sotera Health Co $5.17B 67.0x 5.7%
PGNY Progyny, Inc. $2.22B 44.6x 10.4%
AGL agilon health, inc. $1.51B — -2.1%
VMD VIEMED HEALTHCARE, INC. $373.3M 26.5x 20.5%
BRTX BioRestorative Therapies, Inc. $41.3M — -10.3%
CCEL CRYO CELL INTERNATIONAL INC $35.9M — -1.3%
MGRX MANGOCEUTICALS, INC. $5.0M — -26.0%
FMS Fresenius Medical Care AG — — —